Blair House Dental, Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 10 Deer Crossing Tr., Blairsville, GA 30512 Phone: 706-781-3340 Fax: 706-745-4153 |
Ronnie L. Dyer, D.m.d., P.c. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 48 Haralson Pl, Blairsville, GA 30512 Phone: 706-745-9621 Fax: 706-745-9622 |
Richard W. Putnam, Dds, Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 395 Cleveland St, Blairsville, GA 30512 Phone: 706-745-6848 Fax: 706-835-1324 |
Blairsville Dentistry, Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 10 Deer Crossing Trce, Blairsville, GA 30512 Phone: 706-781-3340 |
Family Dentistry Of Blairsville Dentist Medicare: Not Enrolled in Medicare Practice Location: 100 Wesley Mountain Dr, Blairsville, GA 30512 Phone: 706-745-7100 |
Staton Family Dentistry Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 48 Haralson Pl Ste 4, Blairsville, GA 30512 Phone: 706-745-9621 Fax: 706-745-9622 |
News Archive
COVID-19 patients in a clinical trial at Houston Methodist Hospital are responding quickly to the antiviral drug Remdesivir. The trial's criteria allows for the treatment of patients early in their clinical course and, in some cases, at times where they might have otherwise been intubated.
Today, Americord Registry announced a new partnership with Smart Cells International, the first cord blood company in the United Kingdom, as part of its initiatives during Cord Blood Awareness Month (July) to educate parents around the globe on the benefits of cord blood banking.
"Good fortune favors the well prepared," says Paul S. Auerbach, MD, a founder and past President of the Wilderness Medical Society and editor of Wilderness Medicine, 6th Edition, recently published by Elsevier. With some advance reading, individuals planning vacations or outdoor excursions can become familiar with adverse situations and be prepared to handle them.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year.
Blood eosinophil counts do not reliably reflect airway eosinophil concentrations in children with severe, therapy-resistant asthma, and therefore cannot be used to make therapeutic decisions, researchers report.
› Verified 8 days ago